Teva Pharmaceuticals

Generic and Specialty Pharmaceuticals

Health Tech & Life Sciences
Public on TASE on Jan 1951
Public on NYSE on Jan 1982

Company Overview

Snapshot

Founded in January 1901, Teva Pharmaceuticals operates with over 29,000 employees. The company has raised a total of $908M across 5 funding rounds from 5 investors. In April 2026, Teva Pharmaceuticals acquired Emalex Biosciences.

Business overview

Teva Pharmaceuticals is a global pharmaceutical company specializing in the development, production, and marketing of generic drugs, specialty pharmaceuticals, and active pharmaceutical ingredients. Headquartered in Israel, the company's extensive product portfolio includes over 3,600 medicines, manufacturing approximately 120 billion tablets and capsules annually across 70 facilities. Teva operates in 60 countries and is recognized as a leading pharmaceutical company within the Health Tech & Life Sciences sector, focusing on areas such as respiratory, women's health, neurology, and oncology.

Strategic signal

In September 2025, Teva's Emrusolmin received U.S. FDA Fast Track Designation for the treatment of Multiple System Atrophy. This designation signals regulatory recognition of the drug's potential to address an unmet medical need, potentially accelerating its development and review process, which could lead to earlier market access and impact for patients and investors.

Company Intelligence Q&A

What was a significant recent regulatory milestone for Teva Pharmaceuticals?
In September 2025, Teva’s Emrusolmin was granted U.S. FDA Fast Track Designation for the treatment of Multiple System Atrophy, indicating its potential to address serious conditions with unmet medical needs.
What was a key acquisition made by Teva Pharmaceuticals in 2026?
In April 2026, Teva Pharmaceuticals acquired Emalex Biosciences, expanding its portfolio.
What was a recent product approval for Teva Pharmaceuticals in Canada?
In September 2025, Teva and Medincell’s Risperidone LAI received approval in Canada as LONGAVO®.
What was a recent development regarding Teva's schizophrenia therapy?
In September 2024, Teva announced long-term efficacy and safety data for Deutetrabenazine in European patients with Tardive Dyskinesia, and also touted the safety profile of its once-monthly schizophrenia therapy.

External links